Arthroscopy for temporomandibular disorders

Rigon, Marcelo; Pereira, Ligia Maxwell; Bortoluzzi, Marcelo Carlos; Loguércio, Alessandro Dourado; Ramos, Adilson Luiz; Cardoso, Jefferson Rosa

doi:10.1002/14651858.cd006385.pub2

Cited by 38 publications

(26 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Surgical methods of treatment with intra-articular TMD include arthrocentesis. [8] Among invasive treatments, minimally invasive arthrocentesis and intra-articular injection are relatively accepted by patients and are typically used.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy of a centric relation occlusal splint and intra-articular liquid phase concentrated growth factor injection for the treatment of temporomandibular disorders

Yang

Huang

et al. 2017

Medicine

View full text Add to dashboard Cite

The agony that accompanies the incidence and symptoms of temporomandibular disorders (TMDs) is an important concern in the oral and maxillofacial region. The objective of this study was to explore the clinical findings after centric relation occlusal splint (CROS) treatment and intra-articular injection treatment with liquid phase concentrated growth factors (LPCGFs) in patients with disc displacement without reduction (DDWOR).The group under investigation of this retrospective cohort study included patients with DDWOR who received treatment from April 2014 until March 2016. The predictor variable was the therapeutic method. The outcome variables included joint crepitus sound, visual analog scale (VAS) of temporomandibular joint (TMJ) arthralgia, TMD-associated headache, myofascial pain with referral, deviation of the mandible during opening (DoM), and maximal interincisal opening (MIO). At the stage of CROS treatment, evaluation of all variables adopted the individual as the unit; at the stage after LPCGF injection, the evaluation of joint sound adopted the joint as the unit, whereas the other variables adopted the individual as the unit.Among the 29 patients, 6 (20.68%) were males and 23 (79.31%) were females. Distribution by age ranged from 15 to 84 years (mean age 39.55 ± 15.49 years). After CROS treatment, except for the joint crepitus sound, which failed to achieve significant improvement (P > 0.05), other symptoms, such as DOM, TMD-associated headache, myofascial pain with referral, TMJ arthralgia, and MIO, all achieved statistically significant improvements (P < 0.05). After 2 mL of LPCGF was injected once after CROS treatment, 26 joint crepitus sound symptoms were relieved (P < 0.001) after an average of 48.5 ± 64.1 days.CROS alone can alleviate TMD clinical symptoms, except for the joint crepitus sound. Approximately 72.2% of joint crepitus sounds could be improved within 48 days, on average, once 2 mL of LPCGF was injected. Comparisons were still required in the future, with the effects of other therapeutic methods.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical efficacy of a centric relation occlusal splint and intra-articular liquid phase concentrated growth factor injection for the treatment of temporomandibular disorders

Yang

Huang

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…It can now be performed with extremely small-diameter endoscopes, and permits direct removal and treatment of pathologic intra-articular tissues [55]. With proper patient selection, the success rate for arthroscopy can be 85–90% [55, 56]. …”

Section: Introductionmentioning

confidence: 99%

Recent Tissue Engineering Advances for the Treatment of Temporomandibular Joint Disorders

Aryaei

Vapniarsky

et al. 2016

Curr Osteoporos Rep

View full text Add to dashboard Cite

Temporomandibular disorders (TMD) are among the most common maxillofacial complaints and a major cause of orofacial pain. Although, current treatments provide short- and long-term relief, alternative tissue engineering solutions are in great demand. Particularly, the development of strategies, providing long-term resolution of TMD to help patients regain normal function is a high priority. An absolute prerequisite of tissue engineering is to understand normal structure and function. The current knowledge of anatomical, mechanical, and biochemical characteristics of the temporomandibular joint (TMJ) and associated tissues will be discussed, followed by a brief description of current TMD treatments. The main focus is on recent tissue engineering developments for regenerating TMJ tissue components, with or without a scaffold. The expectation for effectively managing TMD is that tissue engineering will produce biomimetic TMJ tissues that recapitulate the normal structure and function of the TMJ.

show abstract

“…In addition to pain, the other signs and symptoms of TMD include headaches, neck ache, ear complaints, jaw joint sounds, limited/asymmetric jaw movements and jaw function disabilities, that collectively deteriorates patient's quality of life significantly [1,2]. The prevalence of TMD in the general population is high with an estimated 40-75 % having at least one sign and 33 % reporting at least one symptom of TMD [3]. Women are more likely to suffer from TMD than men with female to male ratios ranging from 2:1 to 8:1 [1,4,5].…”

Section: Introductionmentioning

confidence: 99%

Stem Cells for Temporomandibular Joint Repair and Regeneration

Zhang

Yap

Toh

2015

Stem Cell Rev and Rep

View full text Add to dashboard Cite

Temporomandibular Disorders (TMD) represent a heterogeneous group of musculoskeletal and neuromuscular conditions involving the temporomandibular joint (TMJ), masticatory muscles and/or associated structures. They are a major cause of non-dental orofacial pain. As a group, they are often multi-factorial in nature and have no common etiology or biological explanations. TMD can be broadly divided into masticatory muscle and TMJ disorders. TMJ disorders are characterized by intra-articular positional and/or structural abnormalities. The most common type of TMJ disorders involves displacement of the TMJ articular disc that precedes progressive degenerative changes of the joint leading to osteoarthritis (OA). In the past decade, progress made in the development of stem cell-based therapies and tissue engineering have provided alternative methods to attenuate the disease symptoms and even replace the diseased tissue in the treatment of TMJ disorders. Resident mesenchymal stem cells (MSCs) have been isolated from the synovia of TMJ, suggesting an important role in the repair and regeneration of TMJ. The seminal discovery of pluripotent stem cells including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have provided promising cell sources for drug discovery, transplantation as well as for tissue engineering of TMJ condylar cartilage and disc. This review discusses the most recent advances in development of stem cell-based treatments for TMJ disorders through innovative approaches of cell-based therapeutics, tissue engineering and drug discovery.

show abstract

Arthroscopy for temporomandibular disorders

Cited by 38 publications

References 34 publications

Clinical efficacy of a centric relation occlusal splint and intra-articular liquid phase concentrated growth factor injection for the treatment of temporomandibular disorders

Clinical efficacy of a centric relation occlusal splint and intra-articular liquid phase concentrated growth factor injection for the treatment of temporomandibular disorders

Recent Tissue Engineering Advances for the Treatment of Temporomandibular Joint Disorders

Stem Cells for Temporomandibular Joint Repair and Regeneration

Contact Info

Product

Resources

About